Clinical Trials | February 25, 2026
Novo Nordisk unveils weight-loss data from REDEFINE 4 trial
CagriSema produced a 23% weight loss at 84 weeks, versus 25.5% for tirzepatide
CagriSema produced a 23% weight loss at 84 weeks, versus 25.5% for tirzepatide
The Phase 2 trial, conducted through Starton’s Sargon Site Network, is expanding from two to six sites across the U.S.
Liraglutide is a drug-device combination formulation used in the treatment of chronic weight management
Prostate cancer is one of the fastest-growing cancers in India, with approximately 37,948 new cases each year
The study will test the company’s lead product, ZI-MA4-1, in patients with advanced solid cancers
The move follows encouraging Phase I data and a series of regulatory wins from the U.S. Food and Drug Administration
The study is a collaboration between AIM, AstraZeneca, and Erasmus Medical Center in the Netherlands
UBT251 appeared to have a safe and well-tolerated profile consistent with incretin-based therapies
Samsung Health users can now order medicines, book lab tests and online consultations through PharmEasy, along with 6 months of complimentary PharmEasy Plus membership
The new lineup features everything from the Color Fixation and Hair Therapy ranges to the Balanced Cleansing Shampoo and Nourishment & Protection Conditioner
Subscribe To Our Newsletter & Stay Updated
